Tirzepatide

Tirzepatide is a 39-amino acid linear peptide that acts as a dual agonist at both GIP and GLP-1 receptors. Its GIP receptor activity (approximately 5x native GIP potency) enhances fat metabolism in adipose tissue, improves insulin sensitivity in peripheral tissues, and may have direct effects on central appetite regulation through hypothalamic GIP receptors. Its GLP-1 receptor activity (comparable to native GLP-1) slows gastric emptying, promotes satiety through hypothalamic POMC neuron activation, and enhances glucose-dependent insulin secretion. The C20 fatty diacid moiety enables albumin binding, extending the half-life to approximately 5 days for once-weekly dosing. The dual mechanism produces additive effects on weight loss and glycemic control that exceed either pathway alone.

The clinical-trial evidence for tirzepatide weight management was developed for the brand-name finished product, not for any compounded preparation. The SURMOUNT trial program evaluated brand-name tirzepatide for weight management across adults with and without type 2 diabetes, including comparisons with and without intensive behavioral therapy. The SURPASS trial program studied brand-name tirzepatide in type 2 diabetes alongside multiple active comparators. The compounded preparation dispensed by the partner pharmacy has not undergone equivalent finished-product efficacy or safety testing; brand-name trial results should be read as evidence about the molecule and its mechanism, not as a guarantee of identical outcomes from the compounded preparation. Your physician will discuss realistic expectations at consultation.

• Dual GIP/GLP-1 mechanism engages two complementary incretin pathways
• Studied for weight management in brand-name clinical trials
• Improved insulin sensitivity and glycemic control studied in brand-name diabetes trials
• Cardiovascular risk-factor improvements (blood pressure, lipids) reported in brand-name data
• Designed for adherence with a consistent weekly schedule set by your physician

• Nausea (most common, usually diminishes over 4-8 weeks)
• Diarrhea
• Decreased appetite (therapeutic but can be pronounced at higher doses)
• Vomiting, especially during dose escalation periods
• Constipation
• Abdominal pain or dyspepsia
• Injection site reactions
• Hair thinning (reported in some patients during rapid weight loss)

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to tirzepatide or its excipients
• History of pancreatitis or active gallbladder disease
• Pregnancy or planning to become pregnant (discontinue at least 2 months before)
• Breastfeeding
• Severe gastrointestinal disease or gastroparesis
• Diabetic retinopathy requiring active treatment (may worsen transiently)

• Insulin and sulfonylureas - significant hypoglycemia risk; dose adjustment typically required
• Oral contraceptives - delayed gastric emptying may reduce bioavailability; use non-oral contraception
• Warfarin and other anticoagulants - monitor INR closely during initiation
• Oral medications with narrow therapeutic index - timing of absorption may be altered
• Acetaminophen - peak absorption delayed; clinical significance is minimal

Follow the storage instructions provided by your pharmacy and on the medication label. Do not use if the solution is cloudy, discolored, or contains visible particles.